Business
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025 NANTES, France, June 11, 6:30 PM – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces the cancellation of the convening of the mixed General Meeting initially scheduled for June 25, 2025 (the « General Meeting ») to clarify the situation. The Board of Directors will convene a new General Meeting within the allotted time frame. Following the publication on June 3, 2025, of a concerted declaration on the websi
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025","length":69,"tagName":"p"},{"type":"text","content":"NANTES, France, June 11, 6:30 PM – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces the cancellation of the convening of the mixed General Meeting initially scheduled for June 25, 2025 (the « General Meeting ») to clarify the situation. The Board of Directors will convene a new General Meeting within the allotted time frame.","length":357,"tagName":"p"},{"type":"text","content":"Following the publication on June 3, 2025, of a concerted declaration on the website of the Autorité des Marchés Financiers and as indicated in the press release of June 9, 20251, OSE Immunotherapeutics requested the President of the Nantes Commercial Court to extend the legal deadline for holding the General Meeting. The President of the Court granted an extension of this deadline until September 30, 2025, by order issued on June 10, 2025.","length":444,"tagName":"p"},{"type":"text","content":"The Board of Directors of OSE Immunotherapeutics has acknowledged this judicial decision and has taken all necessary consequences. It will convene the General Meeting within the now allotted time frame. This period will allow for verifying the regularity and transparency of the General Meeting and ensuring shareholders are well informed.","length":339,"tagName":"p"},{"type":"text","content":"Proxy forms already received become void, and all information regarding the new convocation, agenda, resolution texts, and participation and voting procedures will be communicated in due course.","length":194,"tagName":"p"},{"type":"text","content":"The Board of Directors of OSE Immunotherapeutics, chaired by Didier Hoch, states: “Dear shareholders, we wish to inform you of the postponement of our G...